AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28669789 — intervention group
Group type: COMPARATOR
Intervention: Instructor-led teaching
Number of subjects: 50
Study 26657041 — intervention group
Group type: EXPERIMENTAL
Intervention: e‐Learning + Workshop (e‐L + W)
Number of subjects: 322
Study 26657041 — intervention group
Group type: EXPERIMENTAL
Intervention: e‐Learning (e‐L)
Number of subjects: 322
Study 26657041 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 322
Study 24937205 — intervention group
Group type: COMPARATOR
Intervention: ALA
Number of subjects: 8
Study 24937205 — intervention group
Group type: COMPARATOR
Intervention: PRO
Number of subjects: 8
Study 22747865 — intervention group
Group type: EXPERIMENTAL
Intervention: Ureteroscopic pneumatic lithotripsy (URS)
Number of subjects: 136
Study 22747865 — intervention group
Group type: COMPARATOR
Intervention: Extracorporeal shock wave lithotripsy (ESWL)
Number of subjects: 136
Study 20060288 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin and capecitabine (CX)
Number of subjects: 91
Study 20060288 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin, cisplatin and capecitabine (ECX)
Number of subjects: 91
Study 18257186 — intervention group
Group type: EXPERIMENTAL
Intervention: Cauterization with electric pyropuncture needle (n=84)
Number of subjects: 108
Study 18257186 — intervention group
Group type: COMPARATOR
Intervention: Incision (n=24)
Number of subjects: 108
Study 15929678 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide 2.5 microg b.i.d.
Number of subjects: 156
Study 15929678 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide 5.0 microg b.i.d.
Number of subjects: 156
Study 15929678 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide 7.5 microg b.i.d.
Number of subjects: 156
Study 12789024 — intervention group
Group type: EXPERIMENTAL
Intervention: Suprapubic catheter
Number of subjects: 165
Study 12789024 — intervention group
Group type: COMPARATOR
Intervention: Transurethral catheter
Number of subjects: 165
Study 12789024 — intervention group
Group type: EXPERIMENTAL
Intervention: Suprapubic catheter (excluding those who underwent recatheterization)
Number of subjects: 165
Study 12789024 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient satisfaction
Number of subjects: 165
Study 10591680 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene hydrochloride 60 mg/d
Number of subjects: 56
Study 10591680 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene hydrochloride 150 mg/d
Number of subjects: 56
Study 10591680 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogens (CEEs) 0.625 mg/d
Number of subjects: 56
Study 10591680 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 8734305 — intervention group
Group type: EXPERIMENTAL
Intervention: Meal with 28% lipids
Number of subjects: 0
Study 8734305 — intervention group
Group type: EXPERIMENTAL
Intervention: Meal with 58% lipids
Number of subjects: 0
Study 8734305 — intervention group
Group type: COMPARATOR
Intervention: Both meals
Number of subjects: 0
Study 1661506 — intervention group
Group type: EXPERIMENTAL
Intervention: Cavinton (additional to conventional therapy)
Number of subjects: 61
Study 1661506 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 61
Study 6818707 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate 2 mg/ml
Number of subjects: 10
Study 6818707 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate 10 mg/ml
Number of subjects: 10
Study 6818707 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate 20 mg/ml
Number of subjects: 10
Study 6818707 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate 40 mg/ml
Number of subjects: 10
Study 6818707 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 10
Study 31081350 — intervention group
Group type: EXPERIMENTAL
Intervention: Preplanned changing criterion designs
Number of subjects: 0
Study 31081350 — intervention group
Group type: EXPERIMENTAL
Intervention: Response-guided changing criterion designs
Number of subjects: 0
Study 29925724 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic epidural anesthesia (TEA)
Number of subjects: 300
Study 29925724 — intervention group
Group type: EXPERIMENTAL
Intervention: Intercostal nerve block (INB)
Number of subjects: 300
Study 29925724 — intervention group
Group type: EXPERIMENTAL
Intervention: Paravertebral nerve block (PVB)
Number of subjects: 300
Study 29925724 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 300
Study 27732083 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized acupuncture treatment (AT)
Number of subjects: 76
Study 27732083 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 76
Study 25055057 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh rose flowers as an olfactory stimulant
Number of subjects: 19
Study 25055057 — intervention group
Group type: COMPARATOR
Intervention: Air as a control
Number of subjects: 19
Study 22430237 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant tissue plasminogen activator (n=78)
Number of subjects: 100
Study 22430237 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=22)
Number of subjects: 100
Study 18635681 — intervention group
Group type: EXPERIMENTAL
Intervention: Early discharge programme (EDP)
Number of subjects: 140
Study 18635681 — intervention group
Group type: COMPARATOR
Intervention: Standard discharge programme (SDP)
Number of subjects: 140
Study 17605894 — intervention group
Group type: EXPERIMENTAL
Intervention: NXY-059
Number of subjects: 20
Study 17605894 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 15784786 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intervention focusing on stressors leading to exhaustion and support for recovery
Number of subjects: 710
Study 15784786 — intervention group
Group type: COMPARATOR
Intervention: Usual-care group
Number of subjects: 710
Study 15784786 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intervention
Number of subjects: 710
Study 11932877 — intervention group
Group type: EXPERIMENTAL
Intervention: Joint protection and home hand exercises (JPE group)
Number of subjects: 40
Study 11932877 — intervention group
Group type: COMPARATOR
Intervention: Control group (information session about hand OA)
Number of subjects: 40
Study 10325836 — intervention group
Group type: EXPERIMENTAL
Intervention: PCA with piritramide 0.75 mg
Number of subjects: 60
Study 10325836 — intervention group
Group type: COMPARATOR
Intervention: PCA with piritramide 1.5 mg
Number of subjects: 60
Study 8938545 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated hepatic stellate cells (alpha-SMA+ve) in alcoholic patients
Number of subjects: 38
Study 8938545 — intervention group
Group type: COMPARATOR
Intervention: Activated hepatic stellate cells (alpha-SMA+ve) in control biopsies
Number of subjects: 38
Study 8938545 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of hepatic stellate cells activation with steatosis grade 0
Number of subjects: 38
Study 8938545 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of hepatic stellate cells activation with steatosis grade 1
Number of subjects: 38
Study 8938545 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of hepatic stellate cells activation with steatosis grade 2
Number of subjects: 38
Study 8938545 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of hepatic stellate cells activation with steatosis grade 3
Number of subjects: 38
Study 1679316 — intervention group
Group type: EXPERIMENTAL
Intervention: Nizatidine 300 mg daily
Number of subjects: 43
Study 1679316 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine 800 mg daily
Number of subjects: 43
Study 6848648 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (1.1 ml/kg)
Number of subjects: 32
Study 6848648 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 11777833 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant glycoprotein (RGP) vaccines
Number of subjects: 12
Study 11777833 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 29858875 — intervention group
Group type: EXPERIMENTAL
Intervention: L-PRF membranes
Number of subjects: 8
Study 29858875 — intervention group
Group type: COMPARATOR
Intervention: Free gingival graft (FGG)
Number of subjects: 8
Study 26775293 — intervention group
Group type: EXPERIMENTAL
Intervention: Agomelatine (25mg/d)
Number of subjects: 27
Study 24939364 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopy after locked plating of proximal humeral fractures
Number of subjects: 45
Study 22581487 — intervention group
Group type: EXPERIMENTAL
Intervention: Soap-opera-themed, Thai-language EE video
Number of subjects: 0
Study 22581487 — intervention group
Group type: COMPARATOR
Intervention: Print handout (brochure)
Number of subjects: 0
Study 20372089 — intervention group
Group type: EXPERIMENTAL
Intervention: Live attenuated varicella-zoster virus (VZV) vaccine, two doses 12 weeks apart
Number of subjects: 67
Study 20372089 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study 19060996 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (40 minutes on a cycle-ergometer at 60% of reserve heart rate)
Number of subjects: 50
Study 19060996 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 50
Study 15916369 — intervention group
Group type: EXPERIMENTAL
Intervention: EHF‐IR therapy on biologically active points
Number of subjects: 130
Study 15916369 — intervention group
Group type: COMPARATOR
Intervention: EHF therapy alone
Number of subjects: 130
Study 15916369 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 130
Study 12105828 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin (250 mg intravenous bolus infusion, 20 minutes before endoscopy)
Number of subjects: 105
Study 12105828 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study 12105828 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin and Placebo
Number of subjects: 105
Study 9545623 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard hypocaloric diet + ephedrine (2 x 25 mg) + caffeine (2 x 200 mg)
Number of subjects: 27
Study 9545623 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard hypocaloric diet + ephedrine (2 x 25 mg) + caffeine (2 x 200 mg) + yohimbine (2 x 5 mg)
Number of subjects: 27
Study 9545623 — intervention group
Group type: COMPARATOR
Intervention: Standard hypocaloric diet
Number of subjects: 27
Study 7704057 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient navigator intervention
Number of subjects: 1136
Study 7704057 — intervention group
Group type: COMPARATOR
Intervention: Non-navigated patients
Number of subjects: 1136
Study 7704057 — intervention group
Group type: COMPARATOR
Intervention: Patients with suspicious findings
Number of subjects: 1136
Study 2692698 — intervention group
Group type: EXPERIMENTAL
Intervention: Upright positions (squatting, kneeling, sitting or standing)
Number of subjects: 151
Study 2692698 — intervention group
Group type: COMPARATOR
Intervention: Conventional positions (semi-recumbent and lateral)
Number of subjects: 151
Study 20919 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol 0.5%
Number of subjects: 0
Study 20919 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol 0.25%
Number of subjects: 0
Study 20919 — intervention group
Group type: EXPERIMENTAL
Intervention: Rimiterol 0.5%
Number of subjects: 0
Study 20919 — intervention group
Group type: COMPARATOR
Intervention: Rimiterol 0.5% (second dose 2h after first)
Number of subjects: 0
Study 20919 — intervention group
Group type: EXPERIMENTAL
Intervention: Rimiterol 0.5% (first dose)
Number of subjects: 0
Study 30481998 — intervention group
Group type: EXPERIMENTAL
Intervention: 33 °C
Number of subjects: 938
Study 30481998 — intervention group
Group type: EXPERIMENTAL
Intervention: 36 °C
Number of subjects: 938
Study 30481998 — intervention group
Group type: COMPARATOR
Intervention: Place of residence
Number of subjects: 938
Study 28219815 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin
Number of subjects: 0
Study 28219815 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26289742 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate/salmeterol (FP/SAL) 100/50 mcg
Number of subjects: 339
Study 26289742 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone propionate (FP) 100 mcg
Number of subjects: 339
Study 23835328 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic risk score based on 46 variants
Number of subjects: 5850
Study 21878658 — intervention group
Group type: EXPERIMENTAL
Intervention: Documentation software
Number of subjects: 531
Study 21878658 — intervention group
Group type: EXPERIMENTAL
Intervention: Documentation software plus a timed reminder
Number of subjects: 531
Study 21878658 — intervention group
Group type: EXPERIMENTAL
Intervention: Documentation software, a timed reminder, and an electronic decision support prompt
Number of subjects: 531
Study 21878658 — intervention group
Group type: COMPARATOR
Intervention: Pharmacies without documentation software
Number of subjects: 531
Study 21878658 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall interventions
Number of subjects: 531
Study 19017312 — intervention group
Group type: EXPERIMENTAL
Intervention: Diethylcarbamazine (DEC) treatment
Number of subjects: 59
Study 19017312 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 17026651 — intervention group
Group type: EXPERIMENTAL
Intervention: Poria cocos (PoCo) applied in three concentrations in base cream DAC during the induction period of ICD.
Number of subjects: 0
Study 17026651 — intervention group
Group type: EXPERIMENTAL
Intervention: Poria cocos (PoCo) applied once a day for 5 days after the induction of ICD.
Number of subjects: 0
Study 15615131 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior repositioning splint
Number of subjects: 18
Study 15615131 — intervention group
Group type: EXPERIMENTAL
Intervention: Canine‐protected splint
Number of subjects: 18
Study 15615131 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 18
Study 10954340 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated charcoal (25 g in 200 ml water)
Number of subjects: 9
Study 10954340 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric lavage (10x200 ml)
Number of subjects: 9
Study 10954340 — intervention group
Group type: COMPARATOR
Intervention: Control (200 ml water)
Number of subjects: 9
Study 9310272 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 (PGE1) infusion (120 microg/day) for 7 consecutive days
Number of subjects: 8
Study 7841611 — intervention group
Group type: COMPARATOR
Intervention: Human milk
Number of subjects: 107
Study 7841611 — intervention group
Group type: EXPERIMENTAL
Intervention: WHF 3
Number of subjects: 107
Study 7841611 — intervention group
Group type: EXPERIMENTAL
Intervention: SCHF
Number of subjects: 107
Study 7841611 — intervention group
Group type: EXPERIMENTAL
Intervention: WCHF
Number of subjects: 107
Study 7841611 — intervention group
Group type: EXPERIMENTAL
Intervention: WHF 1 and WHF 2
Number of subjects: 107
Study 7841611 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma amino acid pattern
Number of subjects: 107
Study 3360973 — intervention group
Group type: EXPERIMENTAL
Intervention: 7432-S 25 mg
Number of subjects: 40
Study 3360973 — intervention group
Group type: EXPERIMENTAL
Intervention: 7432-S 50 mg
Number of subjects: 40
Study 3360973 — intervention group
Group type: EXPERIMENTAL
Intervention: 7432-S 100 mg
Number of subjects: 40
Study 3360973 — intervention group
Group type: EXPERIMENTAL
Intervention: 7432-S 200 mg
Number of subjects: 40
Study 3360973 — intervention group
Group type: EXPERIMENTAL
Intervention: 7432-S 100 mg twice daily for 2 weeks
Number of subjects: 40
Study 3360973 — intervention group
Group type: EXPERIMENTAL
Intervention: 7432-S 200 mg twice daily for 1 week
Number of subjects: 40
Study 3360973 — intervention group
Group type: EXPERIMENTAL
Intervention: 7432-S (all doses)
Number of subjects: 40
Study 3360973 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 31106840 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-treatment with antiplatelet drugs (acetylsalicylic acid 15 mg/kg, clopidogrel 11 mg/kg, ticagrelor 27 mg/kg, prasugrel 1.5 mg/kg)
Number of subjects: 0
Study 31106840 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-treatment with antiplatelet drugs
Number of subjects: 0
Study 31106840 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiplatelet drugs
Number of subjects: 0
Study 31106840 — intervention group
Group type: COMPARATOR
Intervention: Control group (no antiplatelet treatment)
Number of subjects: 0
Study 29753703 — intervention group
Group type: EXPERIMENTAL
Intervention: NGR-hTNF 0·8 μg/m2 intravenously plus best investigator choice (n=200)
Number of subjects: 400
Study 29753703 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus best investigator choice (n=200)
Number of subjects: 400
Study 29753703 — intervention group
Group type: EXPERIMENTAL
Intervention: NGR-hTNF 0·8 μg/m2 intravenously
Number of subjects: 400
Study 29753703 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 400
Study 26922845 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilates program
Number of subjects: 101
Study 26922845 — intervention group
Group type: EXPERIMENTAL
Intervention: Trunk strengthening exercise program
Number of subjects: 101
Study 26922845 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 101
Study 23246444 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive heat maintenance jacket (PHM)
Number of subjects: 20
Study 23246444 — intervention group
Group type: COMPARATOR
Intervention: Control (normal training attire)
Number of subjects: 20
Study 21318930 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored web-based intervention
Number of subjects: 171
Study 21318930 — intervention group
Group type: COMPARATOR
Intervention: Non-tailored intervention group
Number of subjects: 171
Study 21318930 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 171
Study 19439517 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole Body Vibration (WBV) training
Number of subjects: 220
Study 19439517 — intervention group
Group type: EXPERIMENTAL
Intervention: Fitness group (cardiovascular, resistance, balance and stretching exercises)
Number of subjects: 220
Study 19439517 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 220
Study 17119469 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant vitamins and minerals (120 mg vitamin C, 30 mg vitamin E, 6 mg beta-carotene, 100 microg selenium, 20 mg zinc)
Number of subjects: 12741
Study 17119469 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12741
Study 15599146 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate individualized training using a computer-controlled patient simulator
Number of subjects: 50
Study 15599146 — intervention group
Group type: COMPARATOR
Intervention: Delayed individualized training using a computer-controlled patient simulator
Number of subjects: 50
Study 15599146 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct observation of interns in actual initial airway events
Number of subjects: 50
Study 11741553 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct stenting
Number of subjects: 399
Study 11741553 — intervention group
Group type: COMPARATOR
Intervention: Stenting after balloon predilatation
Number of subjects: 399
Study 11741553 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients treated later in the study
Number of subjects: 399
Study 9401096 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatosensory evoked potentials (SEPs) with median nerve stimulation
Number of subjects: 36
Study 9401096 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory evoked potentials (AEPs) with binaural stimulation
Number of subjects: 36
Study 9401096 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean arterial pressure (MAP)
Number of subjects: 36
Study 9401096 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart rate (HR)
Number of subjects: 36
Study 7957149 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg
Number of subjects: 12
Study 7957149 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine 0.3 mg
Number of subjects: 12
Study 7957149 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Atenolol and Scopolamine
Number of subjects: 12
Study 7957149 — intervention group
Group type: COMPARATOR
Intervention: Control (no drug)
Number of subjects: 12
Study 2955007 — intervention group
Group type: EXPERIMENTAL
Intervention: Biperiden (intravenous administration)
Number of subjects: 28
Study 2955007 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 28
Study 31994405 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycle ergometer training group (10-minute session, twice a day)
Number of subjects: 228
Study 31994405 — intervention group
Group type: COMPARATOR
Intervention: Standard physiotherapy protocol (10-minute session)
Number of subjects: 228
Study 29653208 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab 120 mg, then 80 mg subcutaneously once every 4 weeks
Number of subjects: 93
Study 27470183 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyceryl trinitrate (GTN) patch applied for 24 hours after surgery
Number of subjects: 200
Study 27470183 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch applied for 24 hours after surgery
Number of subjects: 200
Study 25261199 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 IU/kg prophylaxis
Number of subjects: 74
Study 25261199 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 IU/kg prophylaxis
Number of subjects: 74
Study 25261199 — intervention group
Group type: COMPARATOR
Intervention: On-demand treatment
Number of subjects: 74
Study 22412081 — intervention group
Group type: COMPARATOR
Intervention: ACSM model
Number of subjects: 32
Study 22412081 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodized model
Number of subjects: 32
Study 20852375 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acid capsule, 1 g 3 times a day for 2 months
Number of subjects: 75
Study 20852375 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 2 months
Number of subjects: 75
Study 18285430 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention (twice-weekly classes and once-weekly independent exercise for three months)
Number of subjects: 30